SUN PHARMACEUTICALS LAUNCHING BANANA BOAT "BUG + SUN" FORMULAS in November for the 1994 sun season. Banana Boat Natural Chemical Free Sunscreen offers SPF 8; two sunblocks have SPFs 15 and 25. The products contain zinc and micronized titanium dioxide. Product packaging states that they are "8-hour waterproof" and provide "UVA & UVB protection." The line is replacing the Banana Boat PABA-free line, which included products with SPFs 8, 10 and 25. Banana Boat Bug + Sun Screen SPF 4 and Block SPF 15 include a "natural, no DEET formula" that is in the "citronella family," the company said. Packaging also heralds the products as "8-hour waterproof," with the SPF values appearing in a red cross. Sun Pharmaceuticals also is introducing Baby Block Lotion SPF 50+ for the 1994 season. The firm already markets Baby Sunblock Lotion SPF 29. Both baby sunblock products are "waterproof," feature "UVA & UVB protection," and are PABA-free and for "extra sensitive skin." The new Baby Block contains the active ingredients ethylhexyl p methoxy-cinnamate, 2-ethylhexyl 2 cyano-3, 3-diphenyl acrylate, oxybenzone, 2-ethylhexyl salicylate and titanium dioxide. The company said in sales materials that it is backing all of its sun and skin care products with "over $ 10 mil. support dollars" for promotion and advertising. The materials list promotional activities at "sun-oriented events" such as airshows, festivals and volleyball games as well as in-store programs including sweepstakes and the distribution of over 5 mil. coupons. The firm also is using print ads in women's magazines, radio ads, and co-op sampling with other brands and sampling to dermatologists, pediatricians and hospitals. According to Nielsen Scantrack data for the year ended April 17, Banana Boat held a 15.8% unit share of the sun care market in mass merchandising outlets, second to Schering-Plough, which held a 23.3% share. Schering-Plough markets sun care brands including Coppertone, Shade, Tropical Blend and Water Babies. In food and combo stores, Banana Boat had a 10.2% share, following Schering- Plough with a 42.3% share and Tanning Research Labs' Hawaiian Tropic with a 10.3% share. The brand also was third in drug stores, with a 7.8% unit share. Schering-Plough held 22.4% of the market and Procter & Gamble's Bain de Soleil captured 10.4%. Sun Pharmaceuticals reported that the largest portion of its 1992 dollar sales at retail -- 32% -- came from protection products with SPFs over 15, while 22% was from products with SPF 15 and 11% for SPF 6-14 products. Suntan products with SPFs 0-5 accounted for 25% of retail sales, the firm said, and sunless and self-tanning products generated the remaining 10%.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
